HXT8 Antibody

What is HXK II antibody and what cellular functions does it target?

HXK II antibody (B-8) is a mouse monoclonal IgG2a kappa light chain antibody that specifically recognizes hexokinase II protein of human origin. Hexokinase II catalyzes the critical first step in the glycolytic pathway by converting glucose to glucose-6-phosphate. This enzymatic activity is essential for cellular energy production and metabolic regulation, particularly in tissues with high glucose dependency such as adipose tissue and skeletal muscle. HXK II represents one of four hexokinase isoenzymes, each with unique tissue distribution and regulatory mechanisms. Unlike HXK I (which predominates in brain, kidney, and heart tissues), HXK II is mainly expressed in skeletal muscle and adipose tissue where it plays a crucial role in facilitating glucose uptake in response to insulin signaling .

What detection methods are compatible with HXK II antibody?

HXK II Antibody (B-8) demonstrates versatility across multiple experimental platforms. It can be effectively applied in western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). This broad applicability makes it valuable for multi-modal validation of research findings. The antibody is available in both non-conjugated forms and various conjugated formats including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates (488, 546, 594, 647, 680, and 790), providing researchers with flexibility for different detection systems and experimental designs .

What is HX008 antibody and how does it function in immunotherapy?

HX008 is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1) with an engineered Fc domain. It contains an S228P mutation in the hinge region to prevent IgG4 Fab arm exchange, as well as a triple mutation S254T/V308P/N434A (TPA) in its Fc domain designed to enhance pharmacokinetic properties. HX008 functions by binding with high affinity to human PD-1 and potently suppressing its interaction with both PD-L1 and PD-L2. This blockade reactivates tumor-infiltrating lymphocytes, promoting anti-tumor immune responses. The antibody demonstrates effective T-cell function enhancement comparable to nivolumab (an approved anti-PD-1 therapeutic), while maintaining reduced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) due to its IgG4 backbone .

How should researchers optimize western blotting protocols when using HXK II antibody?

When optimizing western blotting with HXK II antibody, researchers should first consider appropriate sample preparation techniques that preserve the native structure of hexokinase II. For tissues with high expression (skeletal muscle, adipose tissue), lower protein concentrations (15-25 μg) may be sufficient, while other tissues may require 30-50 μg of total protein. Use RIPA buffer supplemented with protease inhibitors for extraction, being mindful that hexokinase II has a molecular weight of approximately 102 kDa.

For optimal results, perform electrophoresis on 8-10% SDS-PAGE gels and transfer to PVDF membranes (preferred over nitrocellulose for this target). Block with 5% non-fat dry milk in TBST for 1 hour at room temperature. For primary antibody incubation, dilute HXK II antibody (B-8) at 1:500 to 1:1000 in blocking buffer and incubate overnight at 4°C. After washing with TBST (3 times, 5 minutes each), apply appropriate secondary antibody conjugated to HRP at 1:5000 dilution for 1 hour at room temperature. The HXK II Antibody (B-8): m-IgG Fc BP-HRP Bundle (sc-529656) or m-IgGκ BP-HRP Bundle (sc-522616) can streamline this process while maintaining specificity .

What are the most effective strategies for evaluating HX008's ability to promote T-cell function?

Based on validated methodologies, researchers can employ multiple complementary approaches to evaluate HX008's capacity to enhance T-cell function. Two particularly effective strategies include:

• Mixed Lymphocyte Reaction (MLR) Assay: This approach involves co-culturing mature dendritic cells with T cells from different donors to induce allogenic T-cell activation. Researchers should supplement culture medium with varying concentrations of HX008 (recommended range: 150-1500 ng/mL or 1-10 nM/L) alongside appropriate controls (isotype control and, ideally, nivolumab as reference). After 48-72 hours of co-culture, collect supernatants and quantify interleukin-2 (IL-2) and interferon-gamma (IFNγ) production via ELISA. Effective PD-1 blockade by HX008 should result in 2-5 fold enhancement of cytokine production compared to isotype control .

• NFAT-Driven Luciferase Reporter Assay: This system utilizes engineered cells including CHO-PD-L1-CD3L (target cells) and Jurkat-PD-1-NFAT (effector cells). Co-culture these cell lines in the presence of varying HX008 concentrations (0.1-10 μg/mL), then measure luminescence after 6-24 hours. Effective PD-1 blockade will yield dose-dependent increases in luciferase expression with EC50 values around 1-1.3 nmol/L when optimized. This system provides quantitative assessment of T-cell activation without the variability associated with primary cell assays .

How can researchers effectively design experiments to study HXK II's role in metabolic disorders?

To effectively study HXK II's role in metabolic disorders, researchers should design multi-dimensional experimental approaches that capture both molecular mechanisms and physiological outcomes. Begin with expression profiling of HXK II across relevant tissues (skeletal muscle, adipose, liver) in both normal and disease models using quantitative immunoblotting with HXK II antibody (B-8). Compare these expression patterns with metabolic parameters like insulin sensitivity and glucose utilization.

For mechanistic studies, combine siRNA or CRISPR-mediated knockdown/knockout of HXK II with metabolic flux analysis using isotope-labeled glucose to trace glycolytic intermediates. Supplement these approaches with co-immunoprecipitation experiments using HXK II Antibody (B-8) AC (sc-374091 AC) to identify novel binding partners that may regulate HXK II activity or subcellular localization.

For translational relevance, analyze HXK II expression and localization in tissue samples from patients with metabolic disorders using immunohistochemistry with HXK II Antibody (B-8) optimized for paraffin-embedded sections. Correlate these findings with clinical parameters including glucose tolerance, insulin resistance indices, and disease progression markers. This comprehensive approach will provide insights into both molecular mechanisms and potential therapeutic targets .

What animal models are most appropriate for evaluating HX008 efficacy, and what methodological considerations are critical?

For evaluating HX008 efficacy, researchers should consider using models that overcome the challenge of species specificity in PD-1 targeting. Two particularly effective models described in the literature include:

• MiXeno Model: This model involves reconstituting human immunity by engrafting adult peripheral blood mononuclear cells (PBMCs) into NSG® (NOD, Prkdc scid, IL2rg null) mice. These immunodeficient mice should be inoculated with human tumor cell lines (such as HCC827) at approximately 5 × 10^6 cells/mouse subcutaneously. Once tumors reach 50-100 mm³, administer freshly isolated human PBMCs (10-15 × 10^6 cells/mouse) intravenously. Begin HX008 treatment (10-30 mg/kg, intraperitoneally) 5-7 days after PBMC engraftment, with treatments typically given twice weekly. Monitor tumor volume regularly (caliber measurements) and collect tissue samples at study endpoints for immunophenotyping analysis using flow cytometry to assess human immune cell infiltration .

• HuGEMM Model: This model utilizes mice genetically engineered to express humanized drug targets. For HX008 studies, use mice with human PD-1 gene knock-in, where mouse exon 2 and 3 are replaced with human counterparts. These chimeric mice express h/mPD-1 protein capable of binding both mouse and human PD-L1 as well as anti-human PD-1 antibodies. Use syngeneic tumor cell lines such as MC38 (murine colon cancer cells) with inoculation at 1-2 × 10^6 cells/mouse. Begin HX008 treatment when tumors reach 50-100 mm³ and monitor for tumor growth inhibition (TGI) and complete response rates .

Critical methodological considerations include validating human PD-1 expression in the models, ensuring consistent engraftment of human PBMCs (for MiXeno), careful titration of antibody dosing, and inclusion of appropriate controls (isotype control and clinically validated anti-PD-1 antibodies like nivolumab) .

How should researchers interpret and troubleshoot conflicting results when comparing HXK II expression across different detection methods?

When encountering conflicting results across different detection methods for HXK II expression, researchers should implement a systematic troubleshooting approach that addresses method-specific variables. First, catalog all discrepancies, noting the direction and magnitude of differences between techniques (e.g., high WB signal but low IHC staining).

For western blotting inconsistencies, verify sample preparation protocols, as membrane-associated HXK II may be differentially extracted depending on buffer composition. Consider using subcellular fractionation to separately analyze cytosolic versus mitochondria-bound HXK II pools. When troubleshooting immunofluorescence or IHC discrepancies, evaluate fixation methods, as overfixation may mask epitopes recognized by the HXK II antibody (B-8).

Cross-validate results using multiple antibody conjugates or detection systems. For instance, if standard IF shows different results than WB, try HXK II Antibody (B-8) with different fluorophore conjugates (FITC vs. Alexa Fluor® 488 or 594) to rule out autofluorescence or detection issues.

For comprehensive validation, incorporate functional assays that measure hexokinase activity to complement expression data. This multi-modal approach provides context for interpreting discrepancies between protein detection methods and enzymatic activity, particularly important in disease states where post-translational modifications may alter enzymatic function without changing expression levels .

What strategies can researchers employ to investigate the relationship between HX008-mediated PD-1 blockade and tumor microenvironment remodeling?

To comprehensively investigate HX008-mediated PD-1 blockade effects on tumor microenvironment remodeling, researchers should implement a multi-parametric approach combining spatial, functional, and temporal analyses:

This integrated approach will provide mechanistic insights beyond simple measurements of tumor volume reduction, potentially identifying early biomarkers of response and resistance mechanisms to HX008 therapy .

What modifications to standard protocols are recommended when using HXK II antibody in co-immunoprecipitation experiments?

When conducting co-immunoprecipitation (co-IP) experiments with HXK II antibody, several modifications to standard protocols are recommended to optimize results while preserving protein-protein interactions:

For sample preparation, use gentle lysis buffers containing 1% NP-40 or 0.5% CHAPS rather than harsh detergents like SDS or deoxycholate, which may disrupt important HXK II protein interactions. Supplement lysis buffers with 10% glycerol to stabilize protein complexes and phosphatase inhibitors to maintain post-translational modifications that may be crucial for interaction partners.

When performing the actual immunoprecipitation, the HXK II Antibody (B-8) AC (sc-374091 AC), which comes pre-conjugated to agarose, offers significant advantages. Use 2-4 μg of antibody-conjugated agarose per 500 μg of total protein lysate. Pre-clear lysates with plain agarose beads (30 minutes at 4°C) before adding the antibody-conjugated beads to reduce non-specific binding.

Extend the incubation time to 6-8 hours or overnight at 4°C with gentle rotation to enhance capture of transient or low-abundance interaction partners. For elution, consider native conditions using competing peptides rather than harsh denaturation with SDS loading buffer if downstream applications require preserved protein structure or enzymatic activity.

For detection of co-immunoprecipitated proteins, perform western blotting using TrueBlot® secondary antibodies to minimize detection of the immunoprecipitating antibody heavy and light chains, which may obscure proteins of interest in the 25-55 kDa range .

How can researchers minimize anti-drug antibody effects when performing pharmacokinetic studies with HX008?

To minimize anti-drug antibody (ADA) effects in pharmacokinetic studies with HX008, researchers should implement several strategic approaches informed by observations from cynomolgus monkey studies where ADA effects were noted:

• Dosing Strategy Optimization: Implement a loading dose followed by maintenance dosing to rapidly achieve steady-state concentrations that may help prevent initial immune recognition. Consider evaluating multiple dosing regimens (10 mg/kg showed good tolerability in cynomolgus studies) with sampling time points optimized based on projected half-life.

• Sample Processing Modifications: Use acid dissociation of serum samples before analysis to disrupt immune complexes between HX008 and ADAs, revealing "masked" drug levels. This provides more accurate PK determinations in the presence of ADAs.

• Immunogenicity Assay Implementation: Develop and validate a multi-tiered approach for ADA detection including screening, confirmation, and characterization assays. Use electrochemiluminescence-based methods with acid dissociation steps to enhance sensitivity for ADA detection.

• Species Selection Considerations: When possible, conduct studies in species with higher homology to human PD-1 to reduce immunogenicity driven by species differences. The cynomolgus monkey model has proven useful despite some ADA effects.

• Concomitant Immunosuppression Evaluation: For critical PK studies, consider evaluating the impact of low-dose immunosuppression (such as methotrexate or low-dose corticosteroids) to temporarily reduce ADA formation during critical sampling periods.

• Data Analysis Approaches: Implement population PK modeling with specific parameters to account for ADA effects, allowing separation of ADA-positive and ADA-negative subjects in analysis to determine the true PK profile unaffected by immunogenicity .

What are the critical factors for optimizing immunohistochemistry with HXK II antibody across different tissue types?

Optimizing immunohistochemistry (IHC) with HXK II antibody across different tissue types requires careful attention to several tissue-specific and technical factors:

• Tissue-Specific Fixation Parameters: Metabolically active tissues (skeletal muscle, adipose tissue) with high HXK II expression require gentler fixation (10% neutral buffered formalin for 12-24 hours) compared to tissues with lower expression. Overfixation can mask epitopes, while underfixation compromises tissue morphology.

• Antigen Retrieval Optimization: Different tissues benefit from customized antigen retrieval. For skeletal muscle, heat-induced epitope retrieval with citrate buffer (pH 6.0) for 20 minutes provides optimal results. For adipose tissue, a milder retrieval using EDTA buffer (pH 9.0) for 15 minutes prevents tissue disruption while maintaining antigen availability.

• Signal Amplification Selection: The baseline expression level of HXK II varies significantly across tissues. For high-expressing tissues (skeletal muscle), standard ABC or polymer detection systems are sufficient. For tissues with lower expression (heart, brain), implement tyramide signal amplification to enhance detection sensitivity without increasing background.

• Counterstain Adjustments: Tissues with high glycogen content may benefit from PAS (Periodic acid–Schiff) counterstaining to correlate HXK II localization with glycogen deposits. For tissues with high lipid content, use Sudan Black B pretreatment to reduce lipofuscin-based autofluorescence that may interfere with chromogenic detection.

• Controls and Validation: Include tissue-matched positive and negative controls for each experiment. For skeletal muscle sections, exercise-stimulated samples serve as excellent positive controls with enhanced HXK II expression. For negative controls, use both isotype antibodies and HXK II-knockout tissue sections (when available) to establish staining specificity .

How does HXK II expression and localization correlate with metabolic disease progression?

HXK II expression and subcellular localization undergo significant alterations during metabolic disease progression, providing both diagnostic indicators and mechanistic insights. In normal insulin-sensitive tissues, HXK II maintains a dynamic equilibrium between cytosolic and mitochondria-bound states, with insulin stimulation promoting mitochondrial association to enhance glucose phosphorylation coupled with oxidative phosphorylation.

As type 2 diabetes progresses, adipose tissue demonstrates progressively declining HXK II expression levels that strongly correlate with worsening glycemic control (r = -0.78, p < 0.001 in clinical studies). Immunohistochemical analysis using HXK II antibody in patient samples reveals that this decline occurs heterogeneously, with visceral adipose showing more pronounced reduction than subcutaneous depots.

In advanced metabolic syndrome with hepatic steatosis, an inappropriate induction of HXK II expression in liver tissue (normally expressing primarily HKIV/glucokinase) disrupts the hepatic glucose sensing apparatus. This ectopic HXK II expression creates a futile cycle of glucose phosphorylation/dephosphorylation that contributes to dysregulated hepatic glucose output .

What are the key considerations for interpreting tumor response data in HX008 preclinical studies?

When interpreting tumor response data in HX008 preclinical studies, researchers must consider several key factors that impact data quality and translational relevance:

• Model-Specific Response Patterns: Different models demonstrate distinct response characteristics. In MiXeno models with HCC827 xenografts and human PBMC engraftment, tumor growth is inherently slower, requiring extended observation periods (>16 days) for meaningful response assessment. By contrast, HuGEMM models with MC38 tumors typically show more rapid kinetics with earlier separation between treatment and control groups.

• Response Metrics Selection: Tumor growth inhibition (TGI) represents a valuable comparative metric, but complete response rates provide critical information about durable responses. In preclinical studies, HX008 demonstrated dose-dependent TGI with statistically significant tumor volume reductions compared to IgG4 control groups. When interpreting these results, calculate both percentage TGI and statistical significance (p-values) to fully characterize response magnitude.

• Inter-Model Comparability: When comparing HX008 efficacy across different model systems, normalize results to reference standards (such as nivolumab) tested in parallel. This approach accounts for model-specific variables that may influence absolute response magnitude.

• Immune Correlates Integration: Tumor volume measurements alone provide limited mechanistic insight. Comprehensive interpretation requires integration with immune correlates including CD8+ T-cell infiltration, activation marker expression, and cytokine profiles within the tumor microenvironment.

• Response Durability Assessment: Extend observation periods beyond initial tumor regression to assess durability of response and potential emergence of resistance. This is particularly important for immune checkpoint inhibitors where delayed responses and pseudoprogression may occur .

How can researchers effectively compare HX008 with other PD-1 inhibitors in functional T-cell assays?

To effectively compare HX008 with other PD-1 inhibitors in functional T-cell assays, researchers should implement a systematic, multi-parameter approach that controls for technical variables while capturing clinically relevant functional differences:

• Concentration Normalization: Rather than using mass-based concentrations alone, implement molar concentration standardization across different antibodies, accounting for potential differences in molecular weight. Test a wide concentration range (0.01-100 nM) to generate complete dose-response curves for accurate EC50 determination.

• Parallel Assay Systems: Employ multiple complementary assay systems simultaneously, including:

  • Mixed lymphocyte reactions measuring multiple cytokines (IL-2, IFNγ, TNFα)

  • NFAT-luciferase reporter systems

  • PD-1/PD-L1 blocking assays using surface plasmon resonance

  • Primary T-cell activation assays with flow cytometry endpoints

• Donor Diversity Strategy: When using primary cells, incorporate T cells from multiple donors (minimum n=6) with diverse HLA backgrounds to account for response heterogeneity. Include both healthy donors and, where available, cancer patient-derived T cells which may have distinct baseline exhaustion profiles.

• Standardized Positive Controls: Include benchmark PD-1 inhibitors with established clinical efficacy (nivolumab, pembrolizumab) as positive controls in each experiment. This allows calculation of relative potency ratios rather than relying solely on absolute values, enhancing cross-study comparability.

• Receptor Occupancy Correlation: Complement functional assays with receptor occupancy measurements using flow cytometry to correlate functional outcomes with target engagement efficiency.

Data from published studies demonstrate that HX008 exhibits comparable T-cell activation potency to nivolumab in both MLR assays (with similar 2-5 fold enhancement of IL-2 and IFNγ production) and NFAT-driven luciferase reporter systems (EC50 values of 1.15 nmol/L for HX008 and 1.30 nmol/L for nivolumab) .

What emerging applications of HXK II antibody might advance understanding of cancer metabolism?

Emerging applications of HXK II antibody have significant potential to advance understanding of cancer metabolism through several innovative research directions:

• Spatial Metabolic Heterogeneity Mapping: Combining HXK II immunohistochemistry with multiplexed imaging technologies can reveal intratumoral metabolic zones with distinct glycolytic capacities. Using HXK II Antibody (B-8) with spatial transcriptomics approaches will allow correlation of enzyme localization with regional gene expression profiles, revealing microenvironmental factors driving metabolic compartmentalization within tumors.

• Therapy-Induced Metabolic Adaptations: Monitoring HXK II expression and subcellular localization before and after cancer treatments (chemotherapy, radiation, targeted therapies) can uncover adaptive metabolic reprogramming mechanisms. Such studies may identify metabolic vulnerabilities that emerge during treatment, presenting opportunities for combination therapies targeting glycolytic adaptation.

• Cancer Stem Cell Metabolic Phenotyping: Using HXK II antibody to characterize metabolic profiles of cancer stem cell populations may reveal distinct energy production strategies that support stemness and therapy resistance. Flow cytometry with HXK II Antibody (B-8) PE or FITC conjugates enables correlation of stemness markers with HXK II expression at single-cell resolution.

• Metastatic Progression Metabolic Tracking: Comparative analysis of HXK II expression and localization between primary tumors and corresponding metastatic lesions can identify metabolic adaptations that facilitate successful colonization of distant sites. This application may reveal whether glycolytic reprogramming precedes or follows metastatic spread.

• Liquid Biopsy Development: Exploring the presence of HXK II in extracellular vesicles using HXK II antibody may enable development of blood-based biomarkers reflecting tumor metabolic activity. This non-invasive approach could potentially monitor treatment response and disease progression through metabolic signatures .

How might combinations of HX008 with other immunotherapeutic agents enhance antitumor efficacy?

• Dual Immune Checkpoint Inhibition: Combining HX008 with antibodies targeting non-overlapping immune checkpoints (CTLA-4, LAG-3, TIM-3, TIGIT) could synergistically enhance T-cell activation by removing multiple inhibitory signals simultaneously. Preclinical evaluation should examine both concurrent and sequential administration strategies, as timing may significantly impact both efficacy and immune-related adverse events.

• Immunogenic Cell Death Inducers: Pairing HX008 with therapies that promote immunogenic cell death (certain chemotherapies, radiotherapy, or oncolytic viruses) may enhance tumor antigen release and presentation, providing a more robust antigenic stimulus for T-cells activated through PD-1 blockade. This approach addresses the limitation of PD-1 blockade in immunologically "cold" tumors with low mutational burden.

• Metabolic Modulators: Combining HX008 with agents targeting tumor metabolism (such as IDO1 inhibitors or adenosine pathway antagonists) could alleviate metabolic immunosuppression within the tumor microenvironment, creating more favorable conditions for T-cell function following PD-1 blockade.

• Adoptive Cell Therapies: Integrating HX008 with CAR-T or TIL therapies may prevent exhaustion of transferred cells through continuous PD-1 blockade. Preclinical studies should evaluate both concomitant administration and incorporation of HX008 during ex vivo expansion phases of adoptive cell protocols.

• Targeted Therapies with Immunomodulatory Effects: For specific tumor types, combining HX008 with appropriate targeted therapies (BRAF/MEK inhibitors in melanoma, EGFR inhibitors in lung cancer) may enhance efficacy through complementary mechanisms including increased antigen presentation and reduction of immunosuppressive soluble factors .

What novel methodological approaches might enhance detection sensitivity and specificity when using HXK II antibody in low-expression tissues?

To enhance detection sensitivity and specificity when using HXK II antibody in tissues with low expression levels, researchers can implement several innovative methodological approaches:

• Proximity Ligation Assay (PLA) Integration: Adapting the HXK II Antibody (B-8) for proximity ligation assays can dramatically increase detection sensitivity by generating fluorescent signals only when target molecules are in close proximity. This approach is particularly valuable for detecting HXK II interactions with binding partners (like mitochondrial proteins) in tissues with low baseline expression.

• Tyramide Signal Amplification (TSA) Protocol Optimization: Implementing multi-round TSA with HXK II antibody can achieve up to 100-fold signal enhancement while maintaining specificity. Optimize by using lower primary antibody concentrations (1:2000 dilution) combined with longer incubation times (overnight at 4°C) followed by controlled tyramide deposition (5-8 minutes).

• Microfluidic Immunostaining Platforms: Adapting HXK II immunodetection to microfluidic platforms enables continuous flow of optimized antibody concentrations across tissue sections, enhancing binding kinetics while reducing background. This approach is particularly effective for tissues with high lipid content that typically present detection challenges.

• Quantum Dot Conjugation: Developing quantum dot-conjugated HXK II antibodies provides superior photostability and higher quantum yield compared to conventional fluorophores. This modification is especially valuable for detecting low abundance targets in tissues with high autofluorescence, such as brain and liver.

• Mass Cytometry Adaptation: Converting HXK II antibody detection from fluorescence to mass cytometry (CyTOF) using metal isotope labeling enables exceptional sensitivity with minimal background and no spectral overlap concerns. This approach allows simultaneous detection of HXK II with dozens of other markers in complex tissue environments.

• Computational Image Analysis Enhancement: Implementing advanced deconvolution algorithms and machine learning-based signal extraction can significantly improve detection of weak HXK II signals from background noise in digital images acquired from low-expression tissues .